ClinicalTrials.gg
TerminatedNCT00537511Updated Nov 19, 2019Results posted

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

A Phase 1/2 interventional study of Pomalidomide and Cisplatin in Carcinoma, Small Cell, sponsored by Celgene. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
This study was terminated for administrative reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Carcinoma, Small Cell with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Carcinoma, Small Cell · United States.

Enrollment
27th of 38
22 · median 36
Started
2008
the only one that year
Phase 1/2
7 of 40
1 open now
Registered
14th of 40
by date

Among the 40 studies in Carcinoma, Small Cell with a site in United States, this one is the 27th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2008, is one of 7 in phase 1/2, and was the 14th registered.

Carcinoma, Small Cell

69 studies on the registry are indexed under Carcinoma, Small Cell; 13 are open to participants now.

Browse Carcinoma, Small Cell studies →

Open to participants now

3 of the 40 studies in Carcinoma, Small Cell with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Carcinoma, Small Cell studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Carcinoma, Small Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.

03

Conditions studied

  • Carcinoma, Small Cell

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signature of
  • Age >= 18
  • or cytologically confirmed small cell lung cancer (SCLC)
  • extensive stage SCLC
  • (ECOG) Performance Status 0, 1 or 2
  • that are asymptomatic and do not require control
  • females of child bearing potential must use two forms of

Exclusion criteria

Exclusion Criteria:

  • pregnant or lactating females
  • prior use of cytotoxic chemotherapy
  • surgery within 14 days of study
  • radiation within 14 days of study
  • prior therapy with CC-4047 (pomalidomide), lenalidomide or thalidomide
  • concurrent use or anticipated use of anti-cancer agents
  • (ANC) \< 1500/mm\^3
  • \< 100 x 10\^3/µL
  • serum creatinine >2.5 mg/dL
  • serum glutamic oxaloacetic transaminase () or serum glutamic pyruvic transaminase (SGPT) > 3.0 x (ULN)
  • serum total > 1.8 mg/dL
  • uncontrolled hypercalcemia
  • \<50 mL/min
  • uncontrolled hypertension
  • neuropathy >= grade 2
  • (BMI) >= 40
  • any other active invasive requiring treatment
  • known chronic infection with (HIV), virus (HBV) or virus (HCV)
  • inability or unwillingness to comply with requirements
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Dose-finding arm: Pomalidomide + Cisplatin + Etoposide

    Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m\^2 and IV etoposide 100 mg/m\^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.

    Drug: Pomalidomide · Drug: Cisplatin · Drug: Etoposide

Interventions

  • Also known as: CC-4047, Pomalyst

  • Also known as: Cisplatinum, CDDP, Platin

  • Also known as: Etoposide phosphate, VP-16, Etopophos

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment. The MTD Phase included the Treatment period (Cycle 1: Identification of the MTD) and the Extension period (Cycles 2 to 6: Confirmation of Safety of the MTD). (See Secondary Outcome Measure 2 for data on DLTs.)

    Time frame: Cycle 1 (21 days)

Secondary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase

    For the purposes of determining the MTD (see Primary Outcome Measure), a DLT was defined as any 1 or more of the following: inability to deliver all 3 doses of cisplatin and etoposide due to toxicity; inability to deliver 14 consecutive days of daily pomalidomide dosing because the participant did not tolerate the medication due to any of the following: ≥ grade 3 non-hematological toxicity (excluding alopecia) occurring before Day 14 of pomalidomide dosing; febrile neutropenia (absolute neutrophil count \[ANC\] \<1,000/µL and fever \>101ºF, core temperature); grade 4 neutropenia of ≥7 days duration with onset on or before Day 14 of pomalidomide dosing; platelet count \<25,000/µL occurring before Day 14 of pomalidomide dosing. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0, grades: 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death.

    Time frame: Cycles 1 - 6 (21-day cycles)

  2. Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)

    Investigator's best assessment of response based on RECIST criteria during the MTD phase. For target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions.

    Time frame: Cycles 1 -6 (21-day cycles)

  3. Duration of Response

    Duration of Response was calculated from first Partial Response (PR) or Complete Response (CR) to disease progression. Duration of response was censored at the last date that the participant was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had been removed from the treatment phase prior to documentation of progression.

    Time frame: From first Partial Response (PR) or Complete Response (CR) to disease progression (maximum of 19.4 weeks)

  4. Overall Survival

    Overall Survival was defined as time (in weeks) from enrollment to death. The median is based on Kaplan-Meier estimate, with 95% confidence intervals about the median overall survival. Overall survival was censored at the last time participant was known to be alive for those who were alive at time of analysis.

    Time frame: From enrollment through study termination (approximately 35 months)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the MTD (Combination Treatment) Phase

    Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death.

    Time frame: Cycles 1-6 (21-day cycles). Median (full range) duration of exposure (in weeks) to pomalidomide (MTD Phase): 1 mg, 17.9 (1.0, 20.3); 3 mg, 17.0 (16.9, 22.0); 4 mg, 14.0 (0.7, 22.0); 5 mg, 13.0 (2.0, 22.1). Cisplatin and etoposide: 15.3 (0.4, 20.6).

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Recovery Period or Maintenance (Monotherapy) Phase

    Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. 'Related' = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death.

    Time frame: Cycle 7 to discontinuation (21-day cycles). Median (full range) duration of exposure (in weeks) to pomalidomide during Maintenance Phase was 5.0 (1.1, 36.0).

07

Results

Posted Apr 17, 2013

Participant flow

Treatment Period (Combination)
Participant flow — Treatment Period (Combination)
MilestonePomalidomide (Overall)
Started22
Intent-to-treat (itt) populaton22
Safety population22
Completed17
Not completed5
Extension Period (Combination)
Participant flow — Extension Period (Combination)
MilestonePomalidomide (Overall)
Started17
Completed11
Not completed6
Recovery Period (Monotherapy)
Participant flow — Recovery Period (Monotherapy)
MilestonePomalidomide (Overall)
Started11
Completed3
Not completed8
Maintenance Phase (Monotherapy)
Participant flow — Maintenance Phase (Monotherapy)
MilestonePomalidomide (Overall)
Started8
Completed0
Not completed8

Outcome measures

PrimaryMaximum Tolerated Dose (MTD)

The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment. The MTD Phase included the Treatment period (Cycle 1: Identification of the MTD) and the Extension period (Cycles 2 to 6: Confirmation of Safety of the MTD). (See Secondary Outcome Measure 2 for data on DLTs.)

Time frame:
Cycle 1 (21 days)
Reported as:
Number · mg
Maximum Tolerated Dose (MTD)
mgPomalidomide (Overall)
Maximum Tolerated Dose (MTD)4
SecondaryNumber of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase

For the purposes of determining the MTD (see Primary Outcome Measure), a DLT was defined as any 1 or more of the following: inability to deliver all 3 doses of cisplatin and etoposide due to toxicity; inability to deliver 14 consecutive days of daily pomalidomide dosing because the participant did not tolerate the medication due to any of the following: ≥ grade 3 non-hematological toxicity (excluding alopecia) occurring before Day 14 of pomalidomide dosing; febrile neutropenia (absolute neutrophil count \[ANC\] \<1,000/µL and fever \>101ºF, core temperature); grade 4 neutropenia of ≥7 days duration with onset on or before Day 14 of pomalidomide dosing; platelet count \<25,000/µL occurring before Day 14 of pomalidomide dosing. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0, grades: 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death.

Time frame:
Cycles 1 - 6 (21-day cycles)
Reported as:
Number · participants
Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase
participantsPomalidomide 1 mgPomalidomide 3 mgPomalidomide 4 mgPomalidomide 5 mg
Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase1002
SecondaryTumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)

Investigator's best assessment of response based on RECIST criteria during the MTD phase. For target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions.

Time frame:
Cycles 1 -6 (21-day cycles)
Reported as:
Number · participants
Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)
participantsPomalidomide 1 mgPomalidomide 3 mgPomalidomide 4 mgPomalidomide 5 mgPomalidomide (Overall, MTD Phase)
Complete Response00000
Partial Response332311
No Change/Stable Disease00000
Progressive Disease11114
Not Assessed00101
Missing20226
SecondaryDuration of Response

Duration of Response was calculated from first Partial Response (PR) or Complete Response (CR) to disease progression. Duration of response was censored at the last date that the participant was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had been removed from the treatment phase prior to documentation of progression.

Time frame:
From first Partial Response (PR) or Complete Response (CR) to disease progression (maximum of 19.4 weeks)
Reported as:
Mean · weeks
Duration of Response
weeksPomalidomide (Overall)
Duration of Response13.2 ± 5.54
SecondaryOverall Survival

Overall Survival was defined as time (in weeks) from enrollment to death. The median is based on Kaplan-Meier estimate, with 95% confidence intervals about the median overall survival. Overall survival was censored at the last time participant was known to be alive for those who were alive at time of analysis.

Time frame:
From enrollment through study termination (approximately 35 months)
Reported as:
Median · weeks
Overall Survival
weeksPomalidomide (Overall)
Overall Survival49.6 (28.0 to 63.9)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) During the MTD (Combination Treatment) Phase

Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death.

Time frame:
Cycles 1-6 (21-day cycles). Median (full range) duration of exposure (in weeks) to pomalidomide (MTD Phase): 1 mg, 17.9 (1.0, 20.3); 3 mg, 17.0 (16.9, 22.0); 4 mg, 14.0 (0.7, 22.0); 5 mg, 13.0 (2.0, 22.1). Cisplatin and etoposide: 15.3 (0.4, 20.6).
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the MTD (Combination Treatment) Phase
participantsPomalidomide 1 mgPomalidomide 3 mgPomalidomide 4 mgPomalidomide 5 mgPomalidomide (Overall, MTD Phase)
≥1 TEAE646622
≥1 TEAE related to pomalidomide (POM)646622
≥1 TEAE related to cisplatin and/or etoposide(C/E)646622
≥1 Grade 3 or higher (GR3+) TEAE646622
≥1 GR 3+ TEAE related to POM324514
≥1 GR 3+ TEAE related to C/E636520
≥1 Serious TEAE313310
≥1 Serious TEAE related to POM21137
≥1 Serious TEAE related to C/E21339
≥1 TEAE leading to (→) withdrawal of POM20226
≥1 TEAE → withdrawal of C/E21126
≥1 TEAE → dose reduction/interruption of POM524415
≥1 TEAE → dose reduction/interruption of C/E333413
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) During the Recovery Period or Maintenance (Monotherapy) Phase

Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. 'Related' = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death.

Time frame:
Cycle 7 to discontinuation (21-day cycles). Median (full range) duration of exposure (in weeks) to pomalidomide during Maintenance Phase was 5.0 (1.1, 36.0).
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Recovery Period or Maintenance (Monotherapy) Phase
participantsPomalidomide (Overall)
≥1 TEAE9
≥1 TEAE related to pomalidomide (POM)8
≥1 TEAE related to cisplatin and/or etoposide (C/E7
≥1 Grade 3 or higher (GR3+) TEAE6
≥1 GR 3+ TEAE related to POM2
≥1 GR 3+ TEAE related to C/E2
≥1 TEAE → dose reduction/interruption of POM2

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were defined as any AE occurring or worsening on or after the first treatment of the study medication and within 30 days after the last dose. See Additional Description for duration of exposure for each treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pomalidomide 1 mg—3/6 (50%)6/6 (100%)
Pomalidomide 3 mg—1/4 (25%)4/4 (100%)
Pomalidomide 4 mg—3/6 (50%)6/6 (100%)
Pomalidomide 5 mg—3/6 (50%)6/6 (100%)
Pomalidomide (Overall)—10/22 (45.5%)22/22 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPomalidomide 1 mgPomalidomide 3 mgPomalidomide 4 mgPomalidomide 5 mgPomalidomide (Overall)
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/60/42/60/62/22
Febrile NeutropeniaBlood and lymphatic system disorders0/61/40/61/62/22
Atrioventricular Block CompleteCardiac disorders0/60/40/61/61/22
Diverticular PerforationGastrointestinal disorders0/60/40/61/61/22
FatigueGeneral disorders1/60/40/60/61/22
Neutropenic InfectionInfections and infestations1/60/40/61/62/22
SepsisInfections and infestations1/60/40/60/61/22
Blood Creatinine IncreasedInvestigations0/60/41/60/61/22
HypoglycaemiaMetabolism and nutrition disorders1/60/40/60/61/22
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/40/60/61/22
Most frequent other events
Showing 10 of 149
Most frequent other events
EventPomalidomide 1 mgPomalidomide 3 mgPomalidomide 4 mgPomalidomide 5 mgPomalidomide (Overall)
FatigueGeneral disorders5/64/46/66/621/22
NauseaGastrointestinal disorders3/62/45/65/615/22
AlopeciaSkin and subcutaneous tissue disorders3/63/41/65/612/22
NeutropeniaBlood and lymphatic system disorders3/62/43/65/613/22
Peripheral sensory neuropathyNervous system disorders2/63/42/62/69/22
ConstipationGastrointestinal disorders3/62/44/64/613/22
DyspnoeaRespiratory, thoracic and mediastinal disorders2/61/44/62/69/22
HeadacheNervous system disorders0/60/44/60/64/22
Decreased appetiteMetabolism and nutrition disorders2/62/44/60/68/22
Oedema peripheralGeneral disorders2/61/43/63/69/22

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)Pomalidomide (Overall)
Mean63.9 ± 8.76
Sex: Female, Male
Sex: Female, Male(Participants)Pomalidomide (Overall)
Female4
Male18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pomalidomide (Overall)
Caucasian (White)22
Non-caucasian0
08

Study locations

6 sites
  • Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology
    Cleveland, Ohio 44106, United States
  • Pennsylvania State University
    Hershey, Pennsylvania 17033, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Juranvinski Cancer Center - Medical Oncology
    Hamilton, Ontario L8V 5C2, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Mc Gill University - Department of Oncology - Clinical Research Program
    Montreal, Quebec H2W 1S6, Canada
09

References and documents

Publications

  • Ellis PM, Jungnelius U, Zhang J, Fandi A, Beck R, Shepherd FA. A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer. J Thorac Oncol. 2013 Apr;8(4):423-8. doi: 10.1097/JTO.0b013e318282707b. Erratum In: J Thorac Oncol. 2019 Aug;14(8):1484. doi: 10.1016/j.jtho.2019.04.003. PubMed 23370364 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2008 to primary completion in Nov 2010, 33 months.

Results were first posted in Apr 2013, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2007
First posted
Oct 1, 2007
StartActual
Feb 1, 2008
Primary completionActual
Nov 1, 2010
CompletionActual
Dec 1, 2010
Results first posted
Apr 17, 2013
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00537511
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 1, 2007
Start date
Feb 1, 2008
Primary completion
Nov 1, 2010
Completion
Dec 1, 2010
Results posted
Apr 17, 2013
Last update
Nov 19, 2019

Study contacts

Ulf Jungnelius, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion